Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2006

View Archived Issues

RF9: the first neuropeptide FF antagonist prevents opioid tolerance

ChemGenex and Merck KGaA sign new three-year alliance agreement

Series A financing at CoLucid Pharmaceuticals

ImmuneRegen BioSciences submits proposal to Department of Defense

Targeting cannabinoid CB2 for bone protection

PPARgamma activation suppresses BACE1 to reduce AD pathophysiology

BioLineRx inlicenses new compounds, updates pipeline progress

Positive toxicology data for Binoxan active ingredient

AlphaVax and Wyeth enhance partnership

Ligand and Organon terminate Avinza copromotion

Boehringer Ingelheim launches RE-VOLUTION program for dabigatran etexilate

IND submission for clinical trials of Myodur in Duchenne muscular dystrophy

New German study evaluates AM-111 in acute sensorineural hearing loss

sanofi-aventis transfers Exubera rights to Pfizer

FDA requests pediatric studies of zolpidem

New Aphios subsidiary to develop antiinfluenza drugs from marine microorganisms

Caprion and Icos form new biomarker research collaboration

Ablynx signs Nanobodies collaboration agreement with Novartis

Novel agents for diabetes reported in recent patent literature

Recent patents describe novel agents for metabolic disorders

Novel therapeutics for neurological disorders reported in recent patent literature

Recent patent discloses novel therapeutic agents for ocular disorders

Continuous antiretroviral therapy found superior to episodic therapy

Data made available on 3G4, mouse equivalent of Tarvacin, in models of pancreatic cancer

alphaB-Crystallin proposed as a novel oncoprotein

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...